Physician profile
Curt T Young
NPI 1750557955
$4,891.90
in general payments reported to CMS, 2019-2025
18 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $356 · 2021: $766 · 2022: $292 · 2023: $709 · 2024: $1,637 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,179.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $910.46 | 2021-2025 | Clareon, Hydrus Microstent, Argos |
| Sight Sciences, INC. | $804.57 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $678.17 | 2022-2025 | Durysta, Vuity, Lumigan |
| Harrow Eye, LLC | $673.97 | 2024-2025 | Iheezo |
| Allergan, INC. | $558.58 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $318.82 | 2020-2025 | Eylea Hd |
| Ivantis, INC | $233.59 | 2020-2021 | |
| Amgen INC. | $169.75 | 2024-2025 | Uplizna, Tepezza |
| Bausch & Lomb Americas INC. | $114.68 | 2024 | Miebo, Xiidra, Vyzulta |
| Genentech USA, INC. | $113.42 | 2019-2025 | Vabysmo, Susvimo |
| Aerie Pharmaceuticals, INC. | $71.17 | 2021 | |
| Astellas Pharma US INC | $69.74 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $39.97 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $38.79 | 2019 | |
| Horizon Therapeutics Plc | $37.08 | 2023 | Tepezza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $20.19 | 2023 | Iluvien |
| Oyster Point Pharma, INC. | $19.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.36 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.